RESEARCH COMPLIANCE AUDITS

IRB Education Meeting May 20, 2014

Research Education

- To protect the rights and welfare of human subjects and research animals
- To promote regulatory compliance and scientific integrity
- To ensure that staff are well trained, managed and supported

Research Compliance

- To identify high-risk areas and to see that appropriate corrective actions are taken
- To confirm program adherence to all applicable laws, regulations, and policies
- To ensure that employee actions are consistent with applicable laws and policies

...To support the development of effective health care innovations for veterans

Types of Audits

Informed Consent & HIPAA Authorization Audits

100% of all documents submitted to the IRB

Triennial Regulatory Audits for:

- Human Research Protection Program
- Research Safety
- Animal Research

"For Cause" Audits

- May be requested by any of the research oversight committees, the ACOS/Research, and/or the Facility Director
- May be a full audit or focused on specific areas

Unscheduled Audits

Types of Audits

- Informed Consent & HIPAA Authorization Audits
 - 100% of all documents submitted to the IRB
- Triennial Regulatory Audits for:
 - Human Research Protection Program
 - Research Safety
 - Animal Research
- "For Cause" Audits
 - May be requested by any of the research oversight committees, the ACOS/Research, and/or the Facility Director
 - May be a full audit or focused on specific areas
- Unscheduled Audits

HRPP Regulatory Audit

- Purpose: To ensure compliance with all VA and other federal requirements for the conduct of human research
- An audit must be performed every three years* for all studies that are still interacting with subjects and/or collecting data
- This audit will be coordinated with the Research Safety Audit if hazards have been identified by SRS.

* More frequent audits may be required, based on such considerations as:

- Involvement of vulnerable populations
- Level of risk
- Phase I or Phase II studies
- Involvement of FDA approved drugs for which there has been a safety warning or a change in the labeling that indicates increased risks
- Issues of noncompliance
- Data breach

Preparing for the Audit

The Research Compliance Officer (RCO) will:

- E-mail the PI and Study Coordinator to schedule the audit and provide a list of documents that should be available for review.
- Review the Protocol History in IRB/SRS records.
- Review the study protocol and the most recent abstract for information regarding the objectives, study design, and progress to date.
- Document training completion dates and Scopes of Practice for study personnel who are currently listed in IRB record.

•

REGULATORY AUDIT PREPARATION TOOL									
Document - Investigator Regulatory Files	Present and Reviewed Y/N/NA	Comments	Document – Investigator Regulatory Files	Present and Reviewed Y/N/NA	Comments				
Protocol & Amendments			R&D Correspondence						
Case Report Forms			Notes-to-File						
IRB Approved Consent Forms -Information Provided to Subjects -HIPAA Forms -Advertisements -Record of Approved Consent Form Versions			Site-Sponsor Correspondence -Conference call minutes -E-mails -Newsletters -Conference calls -Letters, memos, faxes						
Subject Log (current/accurate)			Study Site Personnel Signatures, Qualifications, Training, Scope of Practice, CVs, Delegation						
IRB Correspondence			Signed Attestation or Investigator's Agreement (Sponsor, Institution, FDA)						
IRB Submissions, Notifications, Approvals			Official Documents Letters, Memos, etc.						
Serious Adverse Events/Safety Reports			Signed PI Conflict of Interest/Disclosure Statement						
Investigator Brochure/VA Form 10-9012			Investigational Products Accountability, Handling, Pharmacy, Elsewhere						

Conducting the Audit

The RCO will:

- Describe the audit plan to PI/SC and ask about:
 - The Informed Consent process
 - Confidentiality protections
 - Protocol-required activities
 - Current study personnel and their roles
- Review all communications and required documents in the study file and reconcile with IRB/SRS records.
- Review all SAE/UP Reports and match to IRB records.
- Select and review 10-30 subject files.

ADMINISTRATIVE INFORMATION ¹							
Principal Investigator:	Protocol Title:						
Protocol Number: S			urce of	f Funding	:		
		emic Affiliate		Other:			
Initial F	RB Approval Obtain R&DC Approval? R Letter Obtained?	ned? 	Υ	N	Date Protocol was first approved by IRB:		
□ Stu	ernational Study ² dy involves childre dy involves prisone						
Date of Current Audit:	Auditor(s):						
(check all that apply)		rolling new subjects					
CONTINUING REVIEWS							
		Y	N N	A	COMMENTS		
Did required Continuing Review(s) occur as schedu	led per policy by the l	IRB?					
If NO, did any Research occur during the lapse?							

NOTE: If a human protocol is opened and closed without enrolling human subjects at this site, completing the audit tool to this point satisfies the requirement for the HRPP audit.⁵

	IRB SUBMISSIONS, APPROVALS, AND OTHER ACTIONS ⁶										
PROTOCOL, AMENDMENTS, CONTINUING APPROVAL ETC.		APPROVAL EXPIRATION		RESEARCH & DEVELOPMENT COMMITTEE APPROVAL DATE OR N/A8	SUBMISSION & APPROVAL LETTERS ON FILE? ⁹ Y/N/ N/A	Comments					
	Reconcile	records:									
	Have all protocol amendments been reported to the IRB?										
	• Are o	original IF	RB appro	oval docui	ments in	the PI's study file?					
	• Are a	all require	ed signa	tures, dat	es, and s	tamps present?					
	 Were actions completed within required timeframes? 										

‡ •								
		IRI	B SUBMISS	SIONS, APPROVALS, & OT	HER ACTIONS	- INFORME	ED CONSENT ¹⁰	
Informed Consent Date		Informed Consent Version Number Informed Consent IRB ApprovaL ¹¹		Reason for Revision	RE-CONSENT REQUIRED? ¹² Y/N EQUIVALEN 13		Comments	
	No	ote Co	nsent/	HIPAA Authoriza	tion versi	ons and	d approval periods:	
	•			any gaps in ICF	• •			
	•	• Are	IRB da	ate stamps on al	I forms th	at are ((or were) in use?	
	•	We	re ICF/	HIPAA documen	its revised	d when	necessary?	
	Were appropriate subjects re-consented if required by IRB?							

	LOCAL UNANTICIPATED SERIOUS ADVERSE EVENTS (SAES) UNANTICIPATED PROBLEMS INVOLVING RISKS TO SUBJECTS OR OTHERS (UPRs) SIGNIFICANT SAFETY REPORTS / DATA MONITORING COMMITTEE (DMC) REPORTS ¹⁴										
DATE UPR/SAE OCCURRED 15	UPR/SAE DATE LEARNED OF SUBJECT ID EVENT REPORTED TO REQUIRED TIME PERIOD TIME									RO ¹⁸	
	 Reconcile IRB documents with the PI's study records: Have SAEs/UPs been reported to the IRB as required? Are IRB-stamped original documents in the PI's study file? Were actions completed within required timeframes? 										
			tudy participation	£ Carious							

^{*} \underline{U} – Unanticipated \underline{R} – Related to study participation \underline{S} – Serious

	STUDY STAFF QUALIFICATIONS AND TRAINING ²⁰								
Sitt	SITE PERSONNEL		NO EVIDENCE OF TRAINING EVER BEING COMPLETED Y/N	SCOPE OF PRACTICE OR EQUIVALENT DOCUMENTED ²¹ Y/N/NA	Current WOC? Y/N	Role in Study PI/SC/SI	<u>Comments</u>		
	Are all me	ember	s of the	study tea	am list	ed in th	ne IRB files?		
	 If not, sho 	ould ar	n amend	ment or	notific	ation b	e submitted?		
	 Which inc 	dividua	ıls are e	xposed t	o haza	ards (fo	or Safety Audit)?		
	 Is training current and appropriate for their study responsibilities? 								
	Are all Scopes of Practice on file in the Research Office?								

SUBJECT RECORD REVIEW

INCLUSION/EXCLUSION CRITERIA SHOULD ONLY BE EVALUATED FOR HUMAN SUBJECTS RESEARCH THAT INVOLVES INTERVENTION OF MORE THAN MINIMAL RISK WITH SUBJECTS.

Assess Timing of Consent, Compliance with Eligibility Criteria, ETC.

TOTAL NUMBER OF SUBJECTS WHO PASSED SCREENING AND WERE INCLUDED FOR ANALYSIS IN STUDY IN THIS PERIOD =

IF 10 OR FEWER SUBJECTS IN THIS PERIOD, AUDIT ALL OF THEM

If 11-100 SUBJECTS IN THIS PERIOD, AUDIT 10 OF THEM

IF 101-300 SUBJECTS IN THIS PERIOD, AUDIT 10% OF THEM

If MORE THAN 300 IN THIS PERIOD, AUDIT 30 OF THEM

SUBJECT STUDY ID	DOCUMENTATION THAT CONSENT OBTAINED PRIOR TO INITIATION OF STUDY PROCEDURE S ²²		SUBJECT INCLUDED IN RESEARCH IN PRESENCE OF DOCUMENTATION THAT INC/EXCL CRITERIA WERE NOT MET	
	Y/N/NA	Y/N/NA	Y/N/NA	

- How many subjects did the IRB approve for enrollment?
- How many subjects have been enrolled to date?
- Is the Master Subject Log complete and securely maintained?
- Is the screening/consenting process consistent with the protocol?
- Have signed ICFs/HIPAA Authorizations been audited by the RCO?

Audit Follow-Up

- The RCO gives a verbal report of preliminary findings to the PI/SC at the time of the audit and sends an email update after all required information has been reviewed.
- A written report is submitted to the IRB within two weeks of the audit, and the PI receives a copy from the IRB within one month of the subcommittee review.
- The RCO provides a monthly summary of all audit results to the R&D Committee.
- An annual summary of the RCO's research audit activities is reported to the Facility Director in person and in writing.
- The Director submits an "Annual Facility Director Certification of Research Oversight" report to the Office of Research Oversight.

Common Audit Findings

- Master Subject Log is missing or out-of-date.
- Data sets described as "de-identified" contained PHI.
- Study personnel have expired CITI training.
- A Scope of Practice is not on file for study personnel.
- An IRB-required consenting note is not in CPRS.
- Informed Consents have missing or incorrect dates.
- IRB has not been notified of changes in study personnel.

Significant Audit Findings

If "APPARENT Serious or Continuing Noncompliance" is identified by the RCO during an audit:

- An investigation must be conducted and a written report must be submitted within five business days to the Facility Director, ACOS/R, R&DC Chair, and the IRB.
- At its next convened meeting, the IRB must review the report and determine whether "Serious or Continuing Noncompliance" has occurred.
- Remedial actions involving a specific study or research team must be completed within 90-120 days of the IRB's determination (except in extraordinary circumstances).

Serious or Continuing Noncompliance...

- Involves substantive harm or genuine risk of harm to the safety, rights, or welfare of human subjects, staff, or others.
 - Study procedures were performed before obtaining the subject's informed consent.
 - PHI was sent to an individual who was not listed on the HIPAA Authorization.
 - The wrong study drug was dispensed to a subject.
- Substantively compromises the effectiveness of our human subject protection or human research oversight programs.
 - Research was initiated without written notification from the ACOS for Research that the project may begin.
 - Substantive protocol changes were implemented without IRB approval.
 - Study Coordinator performed tasks outside of the approved scope of practice.
- Reflects a persistent failure to adhere to the laws, regulations, or policies governing human research.
 - Failure to maintain documentation required by the IRB or by the IRB-approved protocol for ten or more subjects
 - Repeatedly late submissions of continuing reviews or reportable events
 - Failure to implement remedial actions within the required timeframes

Research Compliance Officers

Nancy Flemmons, RN, MS x3563 Lead RCO for VISN 23

Deanna Rohde, RN, CCRC x5858 Facility RCO

The Research Compliance Office is located across from the IRB Office in Room 3N-103.